Poietis
closedDevelops and produces human, customized tissues using 4D bioprinting for pharmaceutical and cosmetic applications as well as regenerative medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€5.0m | Early VC | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 184 % | (13 %) | 8 % | (9 %) | (29 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (131 %) | (155 %) | (398 %) | - | (920 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (125 %) | (131 %) | (445 %) | (561 %) | (926 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Poietis is a pioneering company in the field of bioprinting, leveraging its proprietary Next Generation Bioprinting (NGB) platform to advance tissue engineering therapies. The company operates in the biotechnology sector, specifically focusing on high-resolution laser-assisted bioprinting technology. Poietis serves a diverse clientele, including research institutions, pharmaceutical companies, and healthcare providers, who are involved in tissue engineering and regenerative medicine.
The company's business model revolves around the development and commercialization of its NGB platform, which is modular and designed to meet the needs of tissue engineers and researchers. Poietis generates revenue through the sale of its bioprinting systems, as well as through partnerships and collaborations with other entities in the biotech and healthcare sectors.
Poietis was spun off from INSERM and the University of Bordeaux, where its core laser-assisted bioprinting technology was initially developed. The company has since built on this expertise to create a versatile and innovative bioprinting platform that aims to bring advanced tissue engineering solutions to patients.
Keywords: Bioprinting, Tissue Engineering, Regenerative Medicine, Laser-Assisted Technology, Biotechnology, NGB Platform, Modular Systems, Healthcare, Research Institutions, Pharmaceutical Companies.